---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000157"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:18:40.180584+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma Q2 revenue $48.1M (+26% YoY); raises FY revenue guidance to $190-200M; appoints John Shannon CEO

## Summary
- Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.
- Recorlev revenue surged 86% YoY to $13.3M; Gvoke up 28% to $20.0M; Keveyis down 7% to $13.1M due to generics.
- Tightens FY2024 revenue guidance to $190-200M (from $175-200M) and year-end cash to $60-75M.
- John Shannon appointed CEO and Kevin McCulloch promoted to President & COO as part of succession plan.
- Net loss of $15.0M ($0.10 per share); cash and equivalents $77.6M at June 30, 2024.

## SEC filing metadata
- accession: 0001867096-24-000157
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000157/0001867096-24-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000157/xers-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000157
- JSON: https://secwatch.observer/filing/0001867096-24-000157.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.